TITLE

Osiris Snags $225M Contract from DoD for Radiation Therapy

AUTHOR(S)
Young, Donna
PUB. DATE
January 2008
SOURCE
BioWorld Today;1/7/2008, Vol. 19 Issue 4, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the contract received by Osiris Therapeutics Inc. from the U.S. Department of Defense (DoD) to develop mesenchymal stem cell therapy Prochymal to treat gastrointestinal injuries. Under the deal, the DoD will pay $24.7 million to cover the future development costs of Prochymal as a countermeasure for acute radiation syndrome. According to chief executive Randal Mills, up to $4.2 million will be given to the company this year to cover development expenses and overhead costs.
ACCESSION #
28123823

 

Related Articles

  • DOD Issues Interim Rule Regarding Performance of Security Functions.  // Contract Management;May2002, Vol. 42 Issue 5, p56 

    Reports the issuance of an interim rule allowing for contracts to be made with local and state governments for the performance of security functions by the Department of Defense in the U.S. Performance of firefighting and security guard functions; Emphasis of the expense of unit readiness;...

  • DOD, GSA, and NASA Issue Final Rule Regarding Definition of 'Claim' and Terms Relating to Termination.  // Contract Management;Aug2002, Vol. 42 Issue 8, p57 

    Reports the final rule issued by the Department of Defense, General Services Administration, and National Aeronautics and Space Administration on the definitions of claim and terms relating to termination in the U.S. Advantage on the clarification of the rule; Addition of the definition of...

  • DOD, GSA, and NASA Issue Final Rule Regarding Disputes and Incidental Items.  // Contract Management;Aug2002, Vol. 42 Issue 8, p58 

    Reports the final rule issued by the Department of Defense, General Services Administration (GSA), and National Aeronautics and Space Administration to add policies on disputes and incidental items in the U.S. Contracts with Federal Supply Schedule; Elimination on the notification requirement...

  • DOD Issues Proposed Rule Regarding Electronic Submission and Processing of Claims for Contract Payments.  // Contract Management;Aug2002, Vol. 42 Issue 8, p59 

    Reports the proposed rule issued by the U.S. Department of Defense on electronic submission and processing of claims for contract payments. Requirement on contractors on electronic submission; Date of issuance of solicitations; Consideration of subpart in the proposed rule.

  • Availability of the Fiscal Year 2011 United States Special Operations Command (USSOCOM) Inventory List of Contracts for Services. Siegel, Aaron // Federal Register (National Archives & Records Service, Office of;6/27/2012, Vol. 77 Issue 124, p38274 

    The article presents information on the notice issued by the U.S. Department of Defense regarding the availability of the first inventory of activities which are performed pursuant to contracts for services to the public.

  • Airbus, EADS, Northrop Grumman.  // AirGuide Online.com;4/5/2010, p3 

    The article reports on the move of the U.S. Department of Defense to invite Airbus SAS to re-bid in the 35 billion dollar contract to supply 179 tanker planes to the Air Force.

  • Osiris completes purchase of Osteocel business for $137M.  // Medical Device Daily;7/28/2008, Vol. 12 Issue 144, p4 

    The article announces the completion of an arrangement by Osiris Therapeutics with NuVasive for the sale of its Osteocel business to NuVasive in a transaction worth up to $137 million. The transaction was approved by Osiris shareholders which resulted in the payment of $35 million to Osiris....

  • Genzyme, Osiris Ink $1.38B Stem Cell Products Deal. Hollingsworth, Catherine // BioWorld Today;11/5/2008, Vol. 19 Issue 216, p1 

    The article reports on the agreement by Genzyme Corp. and Osiris Therapeutics Inc. to develop and commercialize two stem cell products that would provide Osiris with up to $1.25 million up front. Piper Jaffray analyst Edward Tenthoff says, the payment removes any near-term balance sheet...

  • Genzyme, Osiris Ink Potential $1.38B Deal.  // Bioworld Week;11/10/2008, Vol. 16 Issue 45, p1 

    The article reports that Genzyme Corp. and Osiris Therapeutics Inc. has agreed to develop and commercialize two stem cell products in the U.S. It states that the deal will provide Osiris with up to $1.25 billion in potential payments and $130 million up front. It adds that under the agreement,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics